StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'
February 23, 2024 9:19 AM
Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $32.00.The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Downgrades
Next Articles
Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'
February 23, 2024 9:27 AM
Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'
February 23, 2024 9:25 AM
Canaccord Constructive on Intellia Therapeutics (NTLA), 'Key programs continue to progress on track'
February 23, 2024 7:13 AM
Form S-8 Intellia Therapeutics,
February 22, 2024 4:13 PM
Form 10-K Intellia Therapeutics, For: Dec 31
February 22, 2024 4:03 PM
Form 8-K Intellia Therapeutics, For: Feb 22
February 22, 2024 7:46 AM
Intellia Therapeutics (NTLA) Misses Q4 EPS by 2c
February 22, 2024 7:37 AM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
February 22, 2024 7:30 AM
